Sarepta Therapeutics announced a major restructuring involving the layoff of approximately 500 employees, or 36% of its workforce, to achieve annual cost savings of around $400 million. This move follows safety concerns and patient deaths linked to its Duchenne muscular dystrophy gene therapy drug Elevidys, which has recently received a black box warning for acute liver injury. Sarepta is temporarily pausing shipments of Elevidys to non-ambulatory patients and shifting its R&D focus toward RNA interference (siRNA) therapies targeting rare genetic diseases. The company plans to submit new protocols to the FDA for enhanced immunosuppressive regimens and is exploring strategic alternatives for deprioritized gene therapy programs. Despite these challenges, Sarepta's Duchenne portfolio remains a significant revenue contributor.